- Home
- TGL vs OGEN Comparison
TGL vs OGEN Comparison
Compare TGL & OGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TGL
- OGEN
- Stock Information
- Founded
- TGL 2020
- OGEN 1996
- Country
- TGL United States
- OGEN United States
- Employees
- TGL N/A
- OGEN N/A
- Industry
- TGL Retail: Computer Software & Peripheral Equipment
- OGEN Biotechnology: Pharmaceutical Preparations
- Sector
- TGL Technology
- OGEN Health Care
- Exchange
- TGL Nasdaq
- OGEN Nasdaq
- Market Cap
- TGL 4.8M
- OGEN 4.6M
- IPO Year
- TGL 2022
- OGEN N/A
- Fundamental
- Price
- TGL $1.62
- OGEN $4.28
- Analyst Decision
- TGL
- OGEN
- Analyst Count
- TGL 0
- OGEN 0
- Target Price
- TGL N/A
- OGEN N/A
- AVG Volume (30 Days)
- TGL 4.0M
- OGEN 595.3K
- Earning Date
- TGL 05-15-2025
- OGEN 05-09-2025
- Dividend Yield
- TGL N/A
- OGEN N/A
- EPS Growth
- TGL N/A
- OGEN N/A
- EPS
- TGL N/A
- OGEN N/A
- Revenue
- TGL $1,468,790.00
- OGEN N/A
- Revenue This Year
- TGL N/A
- OGEN N/A
- Revenue Next Year
- TGL N/A
- OGEN N/A
- P/E Ratio
- TGL N/A
- OGEN N/A
- Revenue Growth
- TGL N/A
- OGEN N/A
- 52 Week Low
- TGL $1.26
- OGEN $3.12
- 52 Week High
- TGL $203.50
- OGEN $75.60
- Technical
- Relative Strength Index (RSI)
- TGL 43.01
- OGEN 43.10
- Support Level
- TGL $1.38
- OGEN $3.12
- Resistance Level
- TGL $2.06
- OGEN $9.60
- Average True Range (ATR)
- TGL 0.20
- OGEN 1.04
- MACD
- TGL 0.08
- OGEN -0.12
- Stochastic Oscillator
- TGL 45.00
- OGEN 17.90
About TGL Treasure Global Inc.
Treasure Global Inc has created an online-to-offline e-commerce platform business model offering consumers and merchants instant rebates and affiliate cashback programs, while providing a seamless e-payment solution with rebates in both e-commerce and physical retailers/merchant settings. Its product is an internet application branded ZCITY app, that targets consumers by providing personalized deals based on consumers' purchase history, location and preferences.
About OGEN Oragenics Inc.
Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. The Company operates in one reportable segment, which includes activities related to advancing the development of its concussion drug, ONP-002.